THE HAGUE, Netherlands, June 11, 2021 /PRNewswire/ -- DESCAR-T is the French national registry for patients treated with commercial chimeric antigen receptor (CAR)-T cells across all hematological malignancies aimed to collect real-world data including safety and effectiveness up to 15 years after CAR-T cell infusion. Several complementary
Approximately 50 new patients were registered each month, demonstrating the success of CAR-T therapy. Of the registered patients, CAR-T cells were ordered for 607 patients and 550 had been infused. The median time from CAR-T order to infusion was 50 days. Of the patients who completed CAR-T therapy, 350 pts were infused with Axi-cel and 200 received Tisa-acel. Analyzing the response data from 460 infused patients, we found that 40 % achieved complete remission and 30% achieved partial remission by Day 30. The progression-free survival at 6 months calculated from the time of CAR-T infusion was 44.5% [39.6-49.2] months. In conclusion, our analysis of the DESCAR-T registry confirmed the clinical trial efficacy of CAR-T therapy in the real world.
The results of this study will be presented by Professor Steven Le Gouill in an oral session.
Presenter: Professor Steven Le Gouill
Affiliation: CHU de Nantes, Nantes, France
Abstract: #S216 FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR-T CELLS AND ENROLLED IN DESCAR-T REGISTRY, A FRENCH REAL-LIFE DATABASE FOR CAR-T CELLS IN HEMATOLOGIC MALIGNANCIES.
About the EHA Annual Congress: Every June, EHA organizes its Annual Congress in a major European city. This year, due to the persisting COVID19 pandemic, EHA organizes a virtual Congress for the second time. The Congress is aimed at health professionals working in or interested in the field of hematology.
Website: www.ehaweb.org
Logo - http://mma.prnewswire.com/media/622259/EHA_Logo.jpg
